Patents by Inventor Stephen M. Condon

Stephen M. Condon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IAP Binding Compounds
    Publication number: 20150307448
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Application
    Filed: July 16, 2014
    Publication date: October 29, 2015
    Applicant: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
  • SMAC Mimetic for Treating Myelodysplastic Syndromes
    Publication number: 20150158908
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: January 28, 2015
    Publication date: June 11, 2015
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • SMAC mimetic for treating myelodysplastic syndromes
    Patent number: 8986993
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: March 24, 2015
    Assignee: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. LaPorte, Susan R. Rippin
  • Dimeric IAP Inhibitors
    Publication number: 20140329823
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
    Type: Application
    Filed: July 21, 2014
    Publication date: November 6, 2014
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun DENG, Susan R. Rippin
  • Smac Mimetic Therapy
    Publication number: 20140303090
    Abstract: A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 9, 2014
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventors: Stephen M. Condon, Srinivas K. Chunduru, Yasuhiro Mitsuuchi, James Vince, John Silke
  • Dimeric IAP inhibitors
    Patent number: 8822525
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: September 2, 2014
    Assignee: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
  • IAP binding compounds
    Patent number: 8802716
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPB (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 12, 2014
    Assignee: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
  • SMAC Mimetic
    Publication number: 20140073579
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: November 8, 2013
    Publication date: March 13, 2014
    Applicant: TETRALOGIC PHARMACEUTICALS CORP.
    Inventors: Stephen M. Condon, Yijun DENG, Matthew G. LaPorte, Susan R. Rippin
  • SMAC mimetic
    Patent number: 8603816
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: December 10, 2013
    Assignee: TetraLogic Pharmaceuticals Corp.
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. LaPorte, Susan R. Rippin
  • DIMERIC IAP INHIBITORS
    Publication number: 20130289042
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.
    Type: Application
    Filed: June 25, 2013
    Publication date: October 31, 2013
    Inventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPEN
  • IAP BINDING COMPOUNDS
    Publication number: 20130289075
    Abstract: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPB (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.
    Type: Application
    Filed: June 25, 2013
    Publication date: October 31, 2013
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippin
  • IAP INHIBITORS
    Publication number: 20130274278
    Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 17, 2013
    Inventors: Stephen M. CONDON, Yijun DENG, Matthew D. ALEXANDER, Matthew G. LAPORTE
  • Dimeric IAP inhibitors
    Patent number: 8497297
    Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: July 30, 2013
    Assignee: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Matthew G. LaPorte, Yijun Deng, Susan R. Rippen
  • IAP inhibitors
    Patent number: 8481495
    Abstract: The present invention describes compounds of the formula pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.
    Type: Grant
    Filed: May 25, 2010
    Date of Patent: July 9, 2013
    Assignee: TetraLogic Pharmaceuticals Corporation
    Inventors: Stephen M. Condon, Yijun Deng, Matthew D. Alexander, Matthew G. Laporte
  • IAP inhibitors
    Patent number: 8415486
    Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: April 9, 2013
    Assignee: TetraLogic Pharmaceuticals Corp.
    Inventors: Stephen M. Condon, Yijun Deng, Matthew D. Alexander, Matthew G. Laporte
  • IAP inhibitors
    Patent number: 8399683
    Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: March 19, 2013
    Assignee: TetraLogic Pharmaceuticals
    Inventors: Stephen M. Condon, Matthew G. Laporte
  • SMAC Mimetic
    Publication number: 20130012564
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 10, 2013
    Applicant: TETRALOGIC PHARMACEUTICALS CORP.
    Inventors: Stephen M. CONDON, Yijun DENG, Matthew G. LaPorte, Susan R. Rippin
  • 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
    Patent number: 8283372
    Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.
    Type: Grant
    Filed: June 20, 2010
    Date of Patent: October 9, 2012
    Assignee: TetraLogic Pharmaceuticals Corp.
    Inventors: Stephen M. Condon, Yijun Deng, Matthew G. Laporte, Susan R. Rippin
  • Dimeric IAP Inhibitors
    Publication number: 20120184530
    Abstract: Compounds, compositions, and methods of using such compounds to modulate apoptosis including IAP antagonists are provided herein. Compositions including mimetics of the invention and, optionally, secondary agents, may be used to treat proliferative disorders such as, cancer and autoimmune diseases.
    Type: Application
    Filed: March 27, 2012
    Publication date: July 19, 2012
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventor: Stephen M. CONDON
  • IAP Inhibitors
    Publication number: 20120157390
    Abstract: Smac mimetics that inhibit IAPs.
    Type: Application
    Filed: February 29, 2012
    Publication date: June 21, 2012
    Applicant: TETRALOGIC PHARMACEUTICALS CORPORATION
    Inventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPIN